3
Announcements
Trials
Browse
Landscape
Phase
Phase 4
1
Status
Recruiting
1
Sponsor Class
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
Other hematologic neoplasm
1
Myeloid
1
Conditions
Myeloproliferative Disorders
1
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
1
Blast Crisis
1
Interventions
Cyclophosphamide
8
asciminib
7
fludarabine phosphate
6
fludarabine
5
Mycophenolic Acid
5
nilotinib
3
Whole-Body Irradiation
3
Thiotepa
3
Tacrolimus
3
Imatinib Mesylate
3
Granulocyte Colony-Stimulating Factor
3
Cyclosporine
3
venetoclax
2
Sirolimus
2
Melphalan
2
Filgrastim
2
Dasatinib
2
Cyclosporins
2
treosulfan
1
thymoglobulin
1
selinexor
1
ruxolitinib
1
ponatinib
1
plerixafor
1
olverembatinib
1
midostaurin
1
merphos
1
gilteritinib
1
bosutinib
1
blinatumomab
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
×
bosutinib
×
30 days
×
Clear all
NCT04877522
2026-05-11
Asciminib Roll-over Study
Novartis
Phase 4
Recruiting
347 enrolled